Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
WITHDRAWN
Study Classification
OBSERVATIONAL
Study Start Date
2008-01-31
Study Completion Date
2010-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators wish to compare the difference in both cost and time to result for determining fetal lung maturity for the Lamellar Body Count method and the Fetal Lung Maturity II. Our hypothesis is that the time to result will be significantly less using the Lamellar Body Count method, and the cost associated with this method over the traditional FLM II will be favorable.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Accuracy of Amniotic Fluid Lamellar Body Counting for Evaluating of Fetal Lung Maturity
NCT01463722
Retained Fetal Lung Fluid
COMPLETED
PHASE2
Can Ultrasound Replace Amniocentesis for Confirming Fetal Lung Maturation Among Premature Fetuses?
NCT00720252
Fetal Lung Maturity
TERMINATED
NA
Study of the Pathobiology of Bronchopulmonary Dysplasia in Newborns
NCT00006058
Respiratory Distress Syndrome
Bronchopulmonary Dysplasia
COMPLETED
Risk Factors in Bronchopulmonary Dysplasia (Newborn Lung Project)
NCT00005289
Bronchopulmonary Dysplasia
Lung Diseases
Respiratory Distress Syndrome
COMPLETED
Assessment of Lung Aeration at Birth
NCT01739114
Bronchopulmonary Dysplasia
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Rationale/Background: This pilot study is a prospective cohort analysis of two methods currently available at our institution for the determination of fetal lung maturity (FLM) using amniotic fluid. The investigators wish to explore a cost and time savings potential between these two available tests. The test most utilized for the determination of FLM is the evaluation of phospholipids from the amniotic fluid. In our particular institution, the relationship of surfactant to albumin (S/A ratio) is analyzed using a measured fluorescent polarization called the FLM II procedure performed on the TDx or TDxFLx chemical analyzer which is commercially available from Abbott Labs. This test is time-consuming and not available at all institutions.
Lamellar bodies are lamellated phospholipids that represent a storage form of surfactant (1). Because lamellar body diameter (range, 1-5 µm) is similar to that of small platelets, lamellar body counts (LBCs) can be obtained rapidly with use of the platelet channel of a hematology analyzer. The investigators wish to compare the difference in both cost and time to result for determining FLM for the LBC method and the FLM II. Our hypothesis is that the time to result will be significantly less using the LBC method, and the cost associated with this method over the traditional FLM II will be favorable.
Extensive research has shown the efficacy of analyzing fetal lung maturity using lamellar bodies (2-11). Since the efficacy of this method has been established, the adequacy of the lamellar body count in comparison to the FLM II is not in question in this study. While other studies have speculated that a cost and time savings would exist, no literature was found to answer this precise question. The authors feel this information could benefit the medical community from an economic standpoint.
Amniotic fluid collected at the time of amniotomy on term cesarean sections will be sent to OSUMC laboratory for FLM analysis using both a LBC and the FLM II. Our hypothesis is that both the time to result and cost using the LBC method will be substantially less.
Methodology Mechanism of Testing At present, FLM testing at Oklahoma State University Medical Center (OSUMC) is performed by TDx-FLM chemical analyzer manufactured by Abbott Labs. Most laboratories using the Abbott FLM-II assay for assessing fetal lung maturity follow the manufacturer's recommendations for interpreting the surfactant to albumin ratio. Thus, values greater than 55 mg/g are considered mature and values less than 40 mg/g immature. McElrath et al., reported a probability of respiratory distress syndrome (RDS) of 15% or less can be achieved with a S/A ratio cutoff of 60 mg or more at 28 weeks of gestation, 50 or more at 30 weeks, 40 or more at 33 weeks, 30 or more at 35 weeks, and 20 or more at 37 weeks (12).
Lamellar bodies have been tested on many hospital instruments that are used for the hematology testing at their institutions. The ADVIA 2120 (Siemens Medical Solutions Diagnostics, Tarrytown, NY), which is a flow cytometry system that functions to identify and count specific cells in body fluid, is used in the OSUMC laboratory for hematology and other body fluids. Although it has not been used for LBC in our institution, it certainly has that capability according to the manufacturer (13). Neerhof et. al, recently described a change in the threshold at their particular institution. The level of maturity was increased from 30,000 to 50,000 LB/ul. This resulted in significantly fewer neonatal intensive care unit admissions for RDS (14).
An algorithm to FLM testing first utilizing the LBC has been published by Ventolini et al. This algorithm is pictured in Figure 1 (15). We will incorporate this algorithm into our cost analysis as indeterminate LBC values would have required the FLM II procedure, thus elevating the cost for that patient.
Amniotic fluid will be obtained by the operating surgeon or assistant once amniotomy is made. At least 2 ml of amniotic fluid is required for both tests. The fluid will them be handed off to waiting nursing personnel. Once the amniotic fluid is obtained, LBC and S/A ratios will be sent to the laboratory as a stat order. Laboratory personnel will record the time that the specimen is checked into lab and the time the result is available, which is their standard protocol. These times will be used to calculate the time differences between LBC and S/A ratios. The patient will be identified by their assigned medical record number in the hospital. Details of the LBC protocol using the ADVIA 2120 can be found in Table 1.
We will record results of both studies. When an indeterminate level is obtained using the lamellar body count, a cost for performing the FLM II procedure will be added to the lamellar body count cost for that particular patient. The amount that would have been charged to the patient will be used to calculate the cost savings in our sample size. We will then compare the cost of the LBC, LBC and TDxFLM (if required by our algorithm), and the TDxFLM alone.
Study Population:
The study population will include ten term gestations scheduled for either repeat cesarean section (C/S) or primary C/S for malpresentation. Term will be defined as 37 completed weeks based on a sure last menstrual period or first trimester ultrasound crown rump length measurement.
Consent will be obtained either in the resident clinic or on the morning of the scheduled procedure. The resident investigator or one of the obstetrical residents at OSUMC will consent the patient.. The residents participating in consenting will be given instructions regarding the consent process as well as inclusion/exclusion criteria.
The cost for both laboratory tests will be approximately $45 per patient. The sample size will be limited by a research grant of $500.00 provided by the Osteopathic Founders Foundation. Other funding is in application and expansion of this project will be likely in the future.
Inclusion Criteria:
* Term intrauterine gestations beyond 37 completed weeks with dating calculated by their sure last menstrual period (LMP) using Negel's rule or utilizing a first trimester crown rump length ultrasound.
* Women with a previous C/S scheduled for repeat C/S.
* Women who are undergoing a scheduled C-Section for malpresentation
Exclusion Criteria:
* Presence of gross blood in amniotic sample
* Hematocrit count greater than 1% on ADVIA 2120
* Presence of meconium in sample
* Patients with oligohydramnios defined as an amniotic fluid index of less than 5 cm or polyhydramnios defined as an amniotic fluid index of more than 24 cm.
Early Termination Criteria:
If for any reason the investigators or the obstetrician performing the C/S believe the patient or fetus may be harmed by the extra time required for amniotic fluid collection (albeit short), the patient may be removed from the study without her consent. The volunteer would also have the right to terminate her participation in the study and to terminate the investigators' rights to use the collected fluid or analyzed result at any time.
Collection Sheet Appendix C "Lamellar Body Data Collection Sheet" will be used for the collection and storage of data. All information will be de-identified for the collection, storage and retrieval of information.
Data Collection Only the principle investigator(s) will have access to the patients' data collection sheet. Individual physicians involved in the care of a specific patient will have access to that patient's information. All individuals will be in compliance with HIPPA guidelines as set forth by the university and the medical center. Treatment decisions will not be based on the results of data collected for this study.
The following information will be obtained from the patients chart for entry on the data collection sheet.
1. Maternal age
2. Gravity/Parity
3. Estimated Gestational Age and how that was figured
4. Maternal complications - diabetes, hypertension, PIH, coronary vascular disease, thyroid disease, thrombophilia,
5. Date collected
6. Time collected
7. Time received
8. Time reported - FLM, LB
9. Difference in total times
10. FLM result - mature, intermediate or immature
11. LB result - mature, intermediate or immature
12. Cost for FLM
13. Cost for LB No other data will be collected from any patient charts. The resident investigator will assist in the collection of data and will have qualifications for basic human research and HIPPA training as they fall under the OSU - CHS community of individuals with this privilege. Further, physicians and residents which have direct access to current patients chart in their medical management will determine needs for fluid collections and assist in patient consents.
Analysis: An algebraic expression will be used to determine which procedure is the most time and cost effective. Let P be the proportion of LBC's that have conclusive results. Let X denote an attribute of LBC (say cost or time) and let Y denote the same attribute for FLM II. The following equation asks the question "when are the costs associated with just performing FLM II greater than the costs associated with LBC with the FLM II backup?"
Cost (or time) of LBC with FLM II back up \< Cost (or time) of FLM II
when
X \< P\*Y
In other words: Using LBC is beneficial when the proportion of conclusive results is greater than the proportion of cost of LBC over FLM II.
Confidentiality: All records and lab results will be maintained at Oklahoma State University Medical Center, department of medical records and laboratory storage on the hospital's Meditech system. Research analysis data collection sheets will be de-identified and will be maintained by the Department of Ob/Gyn in a secured location at 717 South Houston Ave, Tulsa OK 74127.
Lamellar bodies are lamellated phospholipids that represent a storage form of surfactant (1). Because lamellar body diameter (range, 1-5 µm) is similar to that of small platelets, lamellar body counts (LBCs) can be obtained rapidly with use of the platelet channel of a hematology analyzer. The investigators wish to compare the difference in both cost and time to result for determining FLM for the LBC method and the FLM II. Our hypothesis is that the time to result will be significantly less using the LBC method, and the cost associated with this method over the traditional FLM II will be favorable.
Extensive research has shown the efficacy of analyzing fetal lung maturity using lamellar bodies (2-11). Since the efficacy of this method has been established, the adequacy of the lamellar body count in comparison to the FLM II is not in question in this study. While other studies have speculated that a cost and time savings would exist, no literature was found to answer this precise question. The authors feel this information could benefit the medical community from an economic standpoint.
Amniotic fluid collected at the time of amniotomy on term cesarean sections will be sent to OSUMC laboratory for FLM analysis using both a LBC and the FLM II. Our hypothesis is that both the time to result and cost using the LBC method will be substantially less.
Methodology Mechanism of Testing At present, FLM testing at Oklahoma State University Medical Center (OSUMC) is performed by TDx-FLM chemical analyzer manufactured by Abbott Labs. Most laboratories using the Abbott FLM-II assay for assessing fetal lung maturity follow the manufacturer's recommendations for interpreting the surfactant to albumin ratio. Thus, values greater than 55 mg/g are considered mature and values less than 40 mg/g immature. McElrath et al., reported a probability of respiratory distress syndrome (RDS) of 15% or less can be achieved with a S/A ratio cutoff of 60 mg or more at 28 weeks of gestation, 50 or more at 30 weeks, 40 or more at 33 weeks, 30 or more at 35 weeks, and 20 or more at 37 weeks (12).
Lamellar bodies have been tested on many hospital instruments that are used for the hematology testing at their institutions. The ADVIA 2120 (Siemens Medical Solutions Diagnostics, Tarrytown, NY), which is a flow cytometry system that functions to identify and count specific cells in body fluid, is used in the OSUMC laboratory for hematology and other body fluids. Although it has not been used for LBC in our institution, it certainly has that capability according to the manufacturer (13). Neerhof et. al, recently described a change in the threshold at their particular institution. The level of maturity was increased from 30,000 to 50,000 LB/ul. This resulted in significantly fewer neonatal intensive care unit admissions for RDS (14).
An algorithm to FLM testing first utilizing the LBC has been published by Ventolini et al. This algorithm is pictured in Figure 1 (15). We will incorporate this algorithm into our cost analysis as indeterminate LBC values would have required the FLM II procedure, thus elevating the cost for that patient.
Amniotic fluid will be obtained by the operating surgeon or assistant once amniotomy is made. At least 2 ml of amniotic fluid is required for both tests. The fluid will them be handed off to waiting nursing personnel. Once the amniotic fluid is obtained, LBC and S/A ratios will be sent to the laboratory as a stat order. Laboratory personnel will record the time that the specimen is checked into lab and the time the result is available, which is their standard protocol. These times will be used to calculate the time differences between LBC and S/A ratios. The patient will be identified by their assigned medical record number in the hospital. Details of the LBC protocol using the ADVIA 2120 can be found in Table 1.
We will record results of both studies. When an indeterminate level is obtained using the lamellar body count, a cost for performing the FLM II procedure will be added to the lamellar body count cost for that particular patient. The amount that would have been charged to the patient will be used to calculate the cost savings in our sample size. We will then compare the cost of the LBC, LBC and TDxFLM (if required by our algorithm), and the TDxFLM alone.
Study Population:
The study population will include ten term gestations scheduled for either repeat cesarean section (C/S) or primary C/S for malpresentation. Term will be defined as 37 completed weeks based on a sure last menstrual period or first trimester ultrasound crown rump length measurement.
Consent will be obtained either in the resident clinic or on the morning of the scheduled procedure. The resident investigator or one of the obstetrical residents at OSUMC will consent the patient.. The residents participating in consenting will be given instructions regarding the consent process as well as inclusion/exclusion criteria.
The cost for both laboratory tests will be approximately $45 per patient. The sample size will be limited by a research grant of $500.00 provided by the Osteopathic Founders Foundation. Other funding is in application and expansion of this project will be likely in the future.
Inclusion Criteria:
* Term intrauterine gestations beyond 37 completed weeks with dating calculated by their sure last menstrual period (LMP) using Negel's rule or utilizing a first trimester crown rump length ultrasound.
* Women with a previous C/S scheduled for repeat C/S.
* Women who are undergoing a scheduled C-Section for malpresentation
Exclusion Criteria:
* Presence of gross blood in amniotic sample
* Hematocrit count greater than 1% on ADVIA 2120
* Presence of meconium in sample
* Patients with oligohydramnios defined as an amniotic fluid index of less than 5 cm or polyhydramnios defined as an amniotic fluid index of more than 24 cm.
Early Termination Criteria:
If for any reason the investigators or the obstetrician performing the C/S believe the patient or fetus may be harmed by the extra time required for amniotic fluid collection (albeit short), the patient may be removed from the study without her consent. The volunteer would also have the right to terminate her participation in the study and to terminate the investigators' rights to use the collected fluid or analyzed result at any time.
Collection Sheet Appendix C "Lamellar Body Data Collection Sheet" will be used for the collection and storage of data. All information will be de-identified for the collection, storage and retrieval of information.
Data Collection Only the principle investigator(s) will have access to the patients' data collection sheet. Individual physicians involved in the care of a specific patient will have access to that patient's information. All individuals will be in compliance with HIPPA guidelines as set forth by the university and the medical center. Treatment decisions will not be based on the results of data collected for this study.
The following information will be obtained from the patients chart for entry on the data collection sheet.
1. Maternal age
2. Gravity/Parity
3. Estimated Gestational Age and how that was figured
4. Maternal complications - diabetes, hypertension, PIH, coronary vascular disease, thyroid disease, thrombophilia,
5. Date collected
6. Time collected
7. Time received
8. Time reported - FLM, LB
9. Difference in total times
10. FLM result - mature, intermediate or immature
11. LB result - mature, intermediate or immature
12. Cost for FLM
13. Cost for LB No other data will be collected from any patient charts. The resident investigator will assist in the collection of data and will have qualifications for basic human research and HIPPA training as they fall under the OSU - CHS community of individuals with this privilege. Further, physicians and residents which have direct access to current patients chart in their medical management will determine needs for fluid collections and assist in patient consents.
Analysis: An algebraic expression will be used to determine which procedure is the most time and cost effective. Let P be the proportion of LBC's that have conclusive results. Let X denote an attribute of LBC (say cost or time) and let Y denote the same attribute for FLM II. The following equation asks the question "when are the costs associated with just performing FLM II greater than the costs associated with LBC with the FLM II backup?"
Cost (or time) of LBC with FLM II back up \< Cost (or time) of FLM II
when
X \< P\*Y
In other words: Using LBC is beneficial when the proportion of conclusive results is greater than the proportion of cost of LBC over FLM II.
Confidentiality: All records and lab results will be maintained at Oklahoma State University Medical Center, department of medical records and laboratory storage on the hospital's Meditech system. Research analysis data collection sheets will be de-identified and will be maintained by the Department of Ob/Gyn in a secured location at 717 South Houston Ave, Tulsa OK 74127.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Respiratory Distress Syndrome
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Term intrauterine gestations beyond 37 completed weeks with dating calculated by their sure last menstrual period (LMP) using Negel's rule or utilizing a first trimester crown rump length ultrasound.
* Women with a previous C/S scheduled for repeat C/S.
* Women who are undergoing a scheduled C-Section for malpresentation
* Women with a previous C/S scheduled for repeat C/S.
* Women who are undergoing a scheduled C-Section for malpresentation
Exclusion Criteria
* Presence of gross blood in amniotic sample
* Hematocrit count greater than 1% on ADVIA 2120
* Presence of meconium in sample
* Patients with oligohydramnios defined as an amniotic fluid index of less than 5 cm or polyhydramnios defined as an amniotic fluid index of more than 24 cm.
* Hematocrit count greater than 1% on ADVIA 2120
* Presence of meconium in sample
* Patients with oligohydramnios defined as an amniotic fluid index of less than 5 cm or polyhydramnios defined as an amniotic fluid index of more than 24 cm.
Eligible Sex
FEMALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Oklahoma State University Center for Health Sciences
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joseph R Johnson, D.O.
Role: PRINCIPAL_INVESTIGATOR
OSU Center for Health Sciences Dept of Ob/Gyn
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oklahoma State University Medical Center
Tulsa, Oklahoma, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Weaver TE, Na CL, Stahlman M. Biogenesis of lamellar bodies, lysosome-related organelles involved in storage and secretion of pulmonary surfactant. Semin Cell Dev Biol. 2002 Aug;13(4):263-70. doi: 10.1016/s1084952102000551.
Reference Type
BACKGROUND
Fakhoury G, Daikoku NH, Benser J, Dubin NH. Lamellar body concentrations and the prediction of fetal pulmonary maturity. Am J Obstet Gynecol. 1994 Jan;170(1 Pt 1):72-6. doi: 10.1016/s0002-9378(94)70386-8.
Reference Type
BACKGROUND
Pearlman ES, Baiocchi JM, Lease JA, Gilbert J, Cooper JH. Utility of a rapid lamellar body count in the assessment of fetal maturity. Am J Clin Pathol. 1991 Jun;95(6):778-80. doi: 10.1093/ajcp/95.6.778.
Reference Type
BACKGROUND
Bowie LJ, Shammo J, Dohnal JC, Farrell E, Vye MV. Lamellar body number density and the prediction of respiratory distress. Am J Clin Pathol. 1991 Jun;95(6):781-6. doi: 10.1093/ajcp/95.6.781.
Reference Type
BACKGROUND
Ashwood ER, Palmer SE, Taylor JS, Pingree SS. Lamellar body counts for rapid fetal lung maturity testing. Obstet Gynecol. 1993 Apr;81(4):619-24.
Reference Type
BACKGROUND
Dalence CR, Bowie LJ, Dohnal JC, Farrell EE, Neerhof MG. Amniotic fluid lamellar body count: a rapid and reliable fetal lung maturity test. Obstet Gynecol. 1995 Aug;86(2):235-9. doi: 10.1016/0029-7844(95)00120-g.
Reference Type
BACKGROUND
Greenspoon JS, Rosen DJ, Roll K, Dubin SB. Evaluation of lamellar body number density as the initial assessment in a fetal lung maturity test cascade. J Reprod Med. 1995 Apr;40(4):260-6.
Reference Type
BACKGROUND
Lee IS, Cho YK, Kim A, Min WK, Kim KS, Mok JE. Lamellar body count in amniotic fluid as a rapid screening test for fetal lung maturity. J Perinatol. 1996 May-Jun;16(3 Pt 1):176-80.
Reference Type
BACKGROUND
Lewis PS, Lauria MR, Dzieczkowski J, Utter GO, Dombrowski MP. Amniotic fluid lamellar body count: cost-effective screening for fetal lung maturity. Obstet Gynecol. 1999 Mar;93(3):387-91. doi: 10.1016/s0029-7844(98)00416-5.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Functional Evaluation of the Fetal Lung by Functional Magnetic Resonance Imaging - Blood Oxygenation Level Dependent (MRI-BOLD), in Congenital Diaphragmatic and Parietal Malformations
NCT04186039
WITHDRAWN
NA
Amniotic Fluid Optical Density Determination as a Test for Assessment of Fetal Lung Maturity.
NCT02332304
COMPLETED
PHASE3
Body Composition of Infants: Follow-up to Placenta and Cord Blood Analyses
NCT01464684
WITHDRAWN
Functional and Lymphocytic Markers of Respiratory Morbidity in Hyperoxic Preemies
NCT01607216
COMPLETED
Assessment of Lung Structure and Function of Infants Born Prematurely
NCT00422305
COMPLETED
Repeatability and Feasibility of Infant Spirometry
NCT01057472
COMPLETED
Infant Pulmonary Mechanics: High Flow Nasal Cannula Versus Nasal CPAP
NCT01939067
WITHDRAWN
PHASE1
Fluid Restriction in Respiratory Distress of the Newborn
NCT03120585
COMPLETED
NA
Antecedents of Bronchopulmonary Dysplasia
NCT00005293
COMPLETED
Fast Assessment of Surfactant Deficiency in Preterm Infants to Speed up Treatment - Validation Study
NCT05615428
COMPLETED
Assessment of the Pulmonary Diffusion Capacity in Healthy Infants and Infants With Chronic Lung Disease
NCT00428038
COMPLETED
Characteristics of Cord Blood Immunologic Parameters of Infants <32 Weeks Gestation
NCT00524394
TERMINATED
Fast Assessment of Surfactant Deficiency in Preterm Infants to Speed up Treatment
NCT05638568
WITHDRAWN
NA
Growth of Airways and Lung Tissues in Premature and Healthy Infants
NCT00419588
COMPLETED
Risk Factors of Neonatal Respiratory Distress for Newborns With Prenatally Diagnosed Congenital Lung Malformations
NCT02352207
COMPLETED
PAL to Improve Oral Feeding for Infants With Chronic Lung Disease
NCT05446389
TERMINATED
NA
Nutritive Sucking Patterns in Premature Infants
NCT04561700
WITHDRAWN
NA
Premature Birth and Its Sequelae in Women
NCT00005376
COMPLETED
Early Lung Function Trajectories: Comparison Between Infants With and Without Intrauterine Growth Restriction.
NCT06919757
RECRUITING
Use of Mesenchymal Stem Cells in Pre-term Patients With Bronchopulmonary Dysplasia.
NCT06270199
RECRUITING
PHASE2
Fetal Tracheal Balloon Study in Diaphragmatic Hernia
NCT00966823
TERMINATED
PHASE2
Lung Function Monitoring During Hypoxemia Episodes
NCT06535074
RECRUITING
Metformin for Premature Infants With Bronchopulmonary Dysplasia
NCT07120971
RECRUITING
EARLY_PHASE1
Gastrointestinal Microbiome Influence on the Development of Bronchopulmonary Dysplasia
NCT03229967
COMPLETED
Impact of Extended CPAP on Bronchopulmonary Dysplasia
NCT05547139
COMPLETED
NA